(Q58236397)

inferred from title

hepatocellular carcinoma

1 reference

Ching-Lung Lai

1

0 references

Johnson Y. N. Lau

2

0 references

Pui-Chee Wu

3

0 references

Henry Ngan

4

0 references

Hau-Tim Chung

5

0 references

Stuart J. Mitchell

6

0 references

Timothy J. Corbett

7

0 references

Anthony W. C. Chow

8

0 references

Hsiang-Ju Lin

NIH conference. Hepatocellular carcinoma

9

0 references

language of work or name

English

0 references

publication date

March 1993

0 references

published in

Hepatology

0 references

volume

17

0 references

issue

3

0 references

page(s)

389-394

0 references

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840170307

Treatment of hepatocellular carcinoma with recombinant leucocyte interferon: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840170307

Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840170307

Serum hepatitis B viral DNA in HBsAg-positive hepatocellular carcinoma treated with interferon or adriamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840170307

Clinical features of hepatocellular carcinoma: Review of 211 patients in Hong Kong

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840170307

7 January 2021

Further experience in treating patients with hepatocellular carcinoma in Uganda

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840170307

7 January 2021

Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840170307

7 January 2021

https://api.crossref.org/works/10.1002%2FHEP.1840170307

1 reference

7 January 2021

Human lymphoblastoid interferon. In vitro and in vivo studies in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840170307

7 January 2021

Clinical, serologic, and immunologic effects of human leukocyte interferon in HBsAg-positive primary hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840170307

7 January 2021

A prospective trial of recombinant human interferon alpha 2B in previously untreated patients with hepatocellular carcinoma. The Gastrointestinal Tumor Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840170307

7 January 2021

https://api.crossref.org/works/10.1002%2FHEP.1840170307

1 reference

7 January 2021

Primary liver cancers in Japan

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840170307

7 January 2021

Alpha interferon for induction of remission in hairy-cell leukemia

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840170307

7 January 2021

Phase II trial of recombinant leukocyte A interferon in patients with advanced chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840170307

7 January 2021

Interferon therapy in myelomatosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840170307

7 January 2021

Recombinant alfa-2b-interferon therapy in untreated, stages A and B chronic lymphocytic leukemia. A preliminary report

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840170307

7 January 2021

Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant alpha-interferon in hepatitis-B carriers.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840170307

7 January 2021